EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress
Mar 05, 2020
– Total revenues of $8.6 million in Q4  2019 and $20.4 million for full year 2019 – –  Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 – – Q4 2019 customer demand for DEXYCU and YUTIQ Increased 111% and 59%, respectively, compared to Q3 2019 – – EYP-1901, a
EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®
Mar 02, 2020
36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction WATERTOWN, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing
EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information
Feb 27, 2020
WATERTOWN, Mass. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fourth quarter and full-year ended December 31, 2019 on Thursday,
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Feb 21, 2020
WATERTOWN, Mass. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Feb 20, 2020
WATERTOWN, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an
EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®
Feb 18, 2020
WATERTOWN, Mass. and NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically Integrated
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion
Feb 03, 2020
  – EYP-1901 combines vorolanib with EyePoint’s bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to potentially reduce injection frequency of currently available treatments– – EYP-1901 FDA Type B Pre-IND meeting completed clarifying the pathway for
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan
Jan 27, 2020
WATERTOWN, Mass. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a fast-growing ophthalmology focused pharmaceutical company in
EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
Jan 23, 2020
- Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are estimated to be between $19.3 - $20.0 million - - Q4 2019 net product revenues are estimated to be between $6.9 - $7.6 million and full-year 2019 net product revenues are estimated to be
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
Nov 19, 2019
WATERTOWN, Mass. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment to its existing debt facility with CRG Servicing LLC
EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
Nov 14, 2019
Veteran biopharmaceutical executive with broad experience at global companies brings more than 25 years of finance, partnering and M&A experience to role WATERTOWN, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company
EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress
Nov 07, 2019
– U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order volume – – YUTIQ customer orders up 17% over Q2 with repeat customers representing
EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
Nov 04, 2019
- DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing
EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®
Nov 01, 2019
DEXYCU to be available to diverse member network of Vizient, the largest GPO in the U.S. WATERTOWN, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic
EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
Oct 24, 2019
WATERTOWN, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 on Thursday,
EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
Oct 02, 2019
WATERTOWN, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the Company’s permanent and specific J-Code for YUTIQ®
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
Sep 27, 2019
WATERTOWN, Mass. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ ® (fluocinolone
EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019
WATERTOWN, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
Sep 09, 2019
WATERTOWN, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals , Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ® (fluocinolone
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Aug 07, 2019
– Company reports total revenue of $7.2 million – – Two commercial product launches in U.S. are underway for DEXYCU ® and YUTIQ ® with 43 sales reps actively targeting uveitis specialists, cataract surgeons and ambulatory surgical centers – – YUTIQ receives specific and permanent J Code, effective
Displaying 21 - 40 of 391
EyePoint Pharmaceuticals